| Name | Title | Contact Details |
|---|
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.
Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Companys principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through ...
Galleon Pharmaceutical is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Creyon Bio is a company that is reinventing drug development from the ground up to make safe, effective oligonucleotide based medicines possible—on demand.
BioBlast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The Company is building a diverse portfolio of product candidates with the potential to address unmet medical needs for incurable diseases. The BioBlast platforms are based on deep understandings of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology.